Back to top
more

Accelerate Diagnostics (AXDX)

(Delayed Data from NSDQ)

$3.84 USD

3.84
351,322

+0.12 (3.23%)

Updated Jan 21, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.25%
2Buy18.80%
3Hold10.34%
4Sell6.03%
5Strong Sell2.82%
S&P50011.35%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (163 out of 254)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 57.14% and -11.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -2.86% and -12.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 2nd

BEP, AXDX, FURY, KBAL, and LUNA have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2021

New Strong Sell Stocks for May 20th

AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021

New Strong Sell Stocks for May 14th

AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2021

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Moves to Strong Buy: Rationale Behind the Upgrade

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Accelerate Diagnostics (AXDX) Stock Stands Out in a Strong Industry

Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Accelerate Diagnostics (AXDX) Q4 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.